key: cord-0838000-9k1kf0qi authors: Gupta, Puneet; Kumar, Surender; Sharma, Shashi S. title: SARS‐CoV‐2 prevalence and maternal‐perinatal outcomes among pregnant women admitted for delivery: Experience from COVID‐19‐dedicated maternity hospital in Jammu, Jammu and Kashmir (India) date: 2021-05-24 journal: J Med Virol DOI: 10.1002/jmv.27074 sha: 6d605f21670a14e0bb5c7ae7c82ef58152ecb3a5 doc_id: 838000 cord_uid: 9k1kf0qi The impact of SARS‐CoV‐2 infection in pregnant women and their neonates is an area of research interest nowadays. To date, there is limited knowledge about SARS‐CoV‐2 prevalence, maternal and perinatal outcomes of pregnant women at term in middle‐ and low‐income countries. In the present retro‐prospective study, medical records of pregnant women admitted for delivery were reviewed from the largest Covid‐19 dedicated Shri Maharaja Gulab Singh (SMGS) maternity hospital. The SARS‐CoV‐2 screening was carried out for all pregnant women admitted for delivery using RT‐PCR. All neonates born from SARS‐CoV‐2‐positive mothers were isolated and tested for SARS‐CoV‐2 infection. Most of the pregnant women (90.6%) were asymptomatic at the time of admission with a low prevalence (3.4%) of SARS‐CoV‐2. A higher rate of asymptomatic prevalence (86.1%) was found among SARS‐CoV‐2‐positive pregnant women. On the basis of the RT‐PCR result (negative vs. positive), statistically significant differences were found for maternal characteristics, such as mean gestational age (37.5 ± 2.2 vs. 36.6 ± 3.3), medical comorbidity (2.9% vs. 7.4%), and maternal outcomes like the C‐section rate (29.8% vs. 58.3%), preterm delivery (14.6% vs. 28.3), and neonatal outcomes like mean birth weight (2840 ± 450 vs. 2600 ± 600), low Apgar score (2.7% vs. 6.48%), and fetal distress (10.9% vs. 22.2%) among SARS‐CoV‐2 negative and positive cases, respectively. No neonate from SARS‐CoV‐2‐positive pregnant women was found to be positive for SARS‐CoV‐2 infection. The novel coronavirus is responsible for the coronavirus disease 2019 (COVID- 19) pandemic and thereby moving an unprecedented public health emergency all around the world. 1 is also termed as a "Systematic Human Development Crisis" by the United Nations Development Programme. 2 pandemic have characterized pregnant women as a vulnerable group in comparison to the general population for developing severe SARS-CoV-2 infection with adverse maternal-perinatal outcomes as well. 5 More than 100 million pregnant women across the globe are at high risk of SARS-Cov 2 infection due to various physiological conditions, such as elevation of the diaphragm, decrease residual lung functional capacity, increased oxygen consumption, edema of mucosal membrane of the respiratory tract, and immune-modulation during pregnancy. Moreover, reports suggest that with viral respiratory infections pregnant women are at a higher risk of obstetric and perinatal complications due to changes in their immune response. 6 The majority of pregnant women have been found to be asymptomatic at the time of admission. 7, 8 Asymptomatic pregnant women admitted for delivery can easily transmit disease among mothers, infants, obstetric care providers, and people in general. Adverse effects of SARS-CoV-2 infection on mothers and neonates emphasized the critical need for universal screening of admitted pregnant women using RT-PCR. [8] [9] [10] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positivity rate has been reported up to 13.5% in asymptomatic pregnant women admitted for delivery. 8, 11 SARS-CoV-2 infection during pregnancy may lead to motherto-child vertical transmission and unfavorable maternal and perinatal outcomes as well. SARS-CoV-2-positive pregnant women have a high risk of cesarean section and premature delivery, decreased Apgar Score, and low birth weight of the newborn. [12] [13] [14] Most of the studies of SARS-CoV-2 infected pregnant women admitted for delivery and their maternal-perinatal outcomes are confined to only high-income countries. Little is known about the prevalence of SARS-CoV-2, and maternal-perinatal outcomes of admitted pregnant women in middle-and low-income countries. India, having the second largest population in the world, comes under the category of a middle-income country with the paucity of data about the rate of SARS-CoV-2 positivity and maternal-perinatal outcomes in pregnant women admitted for delivery. More research work should be focused on maternal and neonatal health issues in India due to the COVID-19 pandemic. 15 To date there are no reports on the rate of SARS-CoV-2 positivity and maternal and perinatal outcomes in pregnant women admitted for delivery in any northern state of India. The aim of the present study is to investigate the rate of SARS-CoV-2 positivity, maternal-perinatal outcomes among pregnant women admitted for delivery in COVID-19 dedicated, Shri Maharaja Gulab Singh (SMGS) maternity hospital located in Jammu region of UT of Jammu and Kashmir (India). The present retrospective cohort study was conducted in COVID-19 dedicated Shri Maharaja Gulab Singh (SMGS) maternity hospital located in Jammu, Jammu and Kashmir (India) between September 1, 2020 and November 30, 2020. Shri Maharaja Gulab Singh (SMGS) maternity hospital is one of the largest maternity hospitals in the Jammu region that provides obstetrical care to nearly 15 000 pregnant women per year. All pregnant women admitted to labor and delivery with no prior history of SARS-CoV-2 positivity were included in the study. At the time of admission, all pregnant women were screened for COVID-19related symptoms like fever, cough, dyspnea, and anosmia. If one or more symptoms were present, the patient was considered to be symptomatic. Apart from that admitted women patients were also inquired about maternal characteristics like age, gestational age at delivery, gravidity, parity, and presence of medical comorbidities like hypertension, diabetes, thyroidism, and so on. If one or more medical comorbidity were present, the patient was considered to have medical comorbidity. Admitted women patients were inquired about pregnancy outcomes such as mode of delivery (C-section or vaginal), type of delivery (term or preterm), and obstetric complications, such as hemoglobin (HB < 10), gestational diabetes mellitus (GDM), pregnancy-induced hypertension (PIH), intrahepatic cholestasis (ICP), antepartum hemorrhage (APH), postpartum hemorrhage (PPH) along with perinatal outcomes (birth weight, Apgar score, fetal distress, neonatal intensive care unit (ICU) Admission, and neonatal deaths). Information regarding the severity of COVID-19 based on the requirement of oxygen support and treatment regimen received (antibiotics, antivirals, and corticosteroids) were also collected from SARS-CoV-2 positive pregnant women admitted for delivery. All neonates born from SARS-CoV-2 positive mothers were isolated and tested for SARS-CoV-2 infection at 6 h and 48-72 h after delivery. Combined nasopharyngeal and oropharyngeal swabs were collected from all pregnant women unless a prior RT-PCR report with no more than 48 h was reported at the time of admission whereas only nasopharyngeal swabs were collected from the infants of SARS-CoV-2 positive mothers. Samples were collected in Hi Viral Transport Medium The RT-PCR amplification from isolated RNA was performed using Meril The statistical analysis was performed using the MedCalc statistical software package for the biomedical sciences. Differences in maternal characteristics, maternal outcomes, obstetric complications, and perinatal outcomes between SARS-CoV-2 negative cases and SARS-CoV-2 positive cases were compared using the independent sample t-test for the continuous variables using 95% confidence intervals. Two-sided p values of less than 0.05 were considered to be statistically significant. In the present cohort, a total of 3165 pregnant women admitted for delivery in Shri Maharaja Gulab Singh (SMGS) maternity hospital have been analyzed during the study period. Out of which, 90.6% (15) SARS-CoV-2 positive symptomatic pregnant women, the most common presenting symptoms were fever (66.6%), cough (60%), dyspnea (46.6%), and anosmia (33.3%; Figure 1 ). Maternal characteristics of all pregnant women admitted for delivery have been summarized in SARS-CoV-2 negative and SARS-CoV-2 positive pregnant women have also been characterized on the basis of maternal outcomes such as type of delivery (term, preterm), mode of delivery (vaginal, cesarean), maternal ICU admission maternal deaths (Table 2) , and obstetric complications, such as HB < 10, GDM, PIH, ICP, APH, and PPH (Table 3) . Among 108 SARS-CoV-2 positive cases, 31 (28.3%) had a pre- Neonates from SARS-CoV-2 negative and SARS-CoV-2 positive pregnant women were also evaluated on the basis of perinatal characteristics such as birth weight (g), 5th-min Apgar score ≤ 7, fetal distress, neonatal ICU admission, neonatal death, and SARS-CoV-2 RT-PCR positivity (Table 3) . (Table 4) . 77% of admitted pregnant women for delivery were asymptomatic. In another study, 84% of pregnant women were found to asymptomatic at the time of admission. 8 Our observed rate of asymptomatic pregnant women is in correlation with other similar studies where more than 90% of pregnant women admitted for delivery were asymptomatic. [17] [18] [19] In the present large cohort, 3.4% prevalence of SARS-CoV-2 positivity was found during the study period. However, the pre- The most common presenting symptom in the current study was fever (66.6%) corroborating to other similar studies. 30, 31 In another study, fever (58%) has been reported as the most presenting symptom followed by cough (50.6%) in symptomatic SARS-CoV-2 positive pregnant women. 32 Another systematic review also revealed fever and cough as most dominant initial symptoms in pregnant women infected with SARS-CoV-2. 33 However, the majority of the previous studies also asserted fever and cough as the most common symptoms in SARS-CoV-2 infected pregnant women. [34] [35] [36] According to reports of Trahan et al., 37 symptoms such as cough (53%), fever (37%), dyspnea (30%), and anosmia (20%) were more frequent in symptomatic SARS-CoV-2 pregnant patients. The most common symptoms cough (72%), runny nose (57%), myalgia (52%), and fever (42%) were reported in another study. 38 In the present study, cough and fever were reported less as well as high in comparison to other studies. Our study demonstrated similarities as well as differences in comparison to past studies on COVID-19 symptoms in pregnant women admitted for delivery. In the present study, the mean maternal age of all pregnant women admitted for delivery was 25 years. In a systematic review, Smith et al. 39 In our study, 28.3% of neonates were born preterm and 58.3% of neonates were delivered by cesarean section with fetal distress in 22.2% of SARS-CoV-2 positive pregnant women. Cesarean delivery rates (58.3%) were found to be higher in comparison to WHO's recommended cesarean delivery rates of 1%-5% to avoid mortality and morbidity in both mother and infants. Antoun et al. 35 In the present study, a statistically significant difference was found between SARS-CoV-2 negative and SARS-CoV-2 positive pregnant women on the basis of maternal and perinatal outcomes such as C-section rate, prematurity, birth weight (g), 5th-min Apgar score, and fetal distress. There are reports suggesting a risk of low birth weight, low Apgar score, fetal distress, and preterm delivery in SARS-CoV-2 infected pregnant women. 40, 41 Tanacan et al. 19 also revealed a statistically significant difference between birth weight (g) and Apgar score at birth among high-and low-risk pregnancy groups during COVID-19 pandemic. Clinical significant differences with no statistically significant differences have been found for C-section rate, prematurity, NICU admission, and neonatal mortality in small sample size studies. 16, 19, 42 The human placenta not only acts as an immunological barrier to the entry of pathogens but is also responsible for maintaining the infection is responsible for overwhelmed production of inflammatory cytokines leading to placental hypoperfusion and subsequent hypoxic-ischemic injury to the placenta. 46 Placental injury accompanied by abnormal uterine perfusion promotes adverse changes such as accelerated villous maturation, increased perivillous and intervillous fibrin deposition, villous infarction, and intervillous thrombosis. 47 Immunomodulatory changes in the placenta are accounted for adverse perinatal outcomes such as preterm birth, fetal growth restriction and even fetal death in case of SARS-CoV-2 positive pregnant women admitted for delivery. 6, 48, 49 Our results are in accordance with previous reports demonstrating that viral infections during pregnancy lead to higher rates of complications in fetuses including spontaneous abortion, premature birth, and intrauterine growth restriction (IUGR) in pregnant women. 6, 50, 51 Before the SARS-CoV-2 pandemic, a cohort study comparing pregnant women with and without pneumonia also affirmed that preterm birth, low birth weight, and fetal growth restriction were significantly more prevalent in women with pneumonia. 52 Management and treatment of SARS-CoV-2 positive pregnant women varied according to the institution. Various therapies such as antibiotics based therapy (cefoperazone, sulbactam, ceftriaxone, cefazolin, and azithromycin), antiviral therapy (lopinavir, ritonavir, remdesivir, oseltamivir, and ganciclovir), corticosteroid therapy (prednisone, dexamethasone, and hydrocortisone), interferon beta, chloroquine, hydroxychloroquine, and ivermectin may be used for effective treatment of SARS-CoV-2 positive pregnant women has been reported by various researchers. [53] [54] [55] [56] Due to the nonavailability of data regarding the safety and efficacy of most of the COVID-19 treatments for pregnant women available in the literature. 57 Various previous studies also asserted comparatively higher obstetric complications in SARS-CoV-2 positive pregnant women in comparison to SARS-CoV-2 negative pregnant women with no statistically significant difference. 60 Therefore, obstetrical complications, particularly related to immune-inflammatory conditions, may have a link to long-term NCD in affected children. 61 Our findings support the hypothesis that SARS-CoV-2 infection is responsible for adverse maternal, obstetric complications, and perinatal outcomes in pregnant women admitted for delivery. In the present study, no neonates from SARS-CoV-2 positive cases showed positive tests for SARS-CoV-2 infection similar to other studies. 20 Our study revealed that SARS-CoV-2 infection in neonates is independent of the mode of delivery rejecting the hypothesis of vertical transmission of SARS-CoV-2 infection. The main strength of our study is the inclusion of the largest COVID 19 dedicated maternity hospital of the region, large sample size, inclusion of both asymptomatic and symptomatic pregnant women, and universal screening using RT-PCR. Apart from that majority of the past similar studies have included SARS-COV-2 positive pregnant women only. In the present study, we have not only analyzed but also have also compared SARS-COV-2 negative and SARS-COV-2 positive pregnant women on the basis of maternal characteristics, maternal and perinatal outcomes as well. The present study has several limitations as well due to its retrospective study design. No maternal serological testing, nonestimation of virus clearance from SARS-COV-2 positive pregnant women, and nonavailability of radiological data are key limitations of our study. In the present study, our experience at a large COVID-19 dedicated Naming the coronavirus disease (COVID-2019) and the virus that causes it COVID-19: new UNDP data dashboards reveal huge disparities among countries in ability to cope and recover Managing COVID-19 in low-and middle-income countries Health equity and COVID-19: global perspectives Effects of coronavirus disease 2019 (COVID-19) on maternal, perinatal and neonatal outcomes: a systematic review Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome Spanish registry of Covid-19 screening in asymptomatic pregnants Universal screening for SARS-CoV-2 in women admitted for delivery Presumed asymptomatic carrier transmission of COVID-19 Screening all pregnant women admitted to labor and delivery for the virus responsible for coronavirus disease 2019 Seroprevalence and presentation of SARS-CoV-2 in pregnancy Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records Coronavirus disease 2019 (COVID-19) and pregnancy: what obstetricians need to know Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia Reproductive, maternal and child health services in the wake of COVID−19: insights from India Universal screening for SARS-CoV-2 infection among pregnant women at Elmhurst Hospital Center Universal SARS-CoV-2 testing of pregnant women admitted for delivery in two Italian regions Universal screening for SARS-CoV-2 before labor admission during Covid-19 pandemic in Madrid The rate of SARS-CoV-2 positivity in asymptomatic pregnant women admitted to hospital for delivery: experience of a pandemic center in Turkey Universal SARS-Cov-2 screening in women admitted for delivery in a large managed care organization Universal screening for SARS-CoV-2 in pregnant women at term admitted to an East London maternity unit Low prevalence of SARS-CoV-2 among pregnant and postpartum patients with universal screening in Clinical implications of universal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing in pregnancy Routine screening for SARS CoV-2 in unselected pregnant women at delivery pregnancy Prevalence of SARS-CoV-2 among patients admitted for childbirth in Southern Connecticut Universal screening identifies asymptomatic carriers of SARS-CoV-2 among pregnant women in India Covid-19 during pregnancy: a case series from an universally tested population from the north of Portugal Clinical course of coronavirus disease-2019 in pregnancy Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and metaanalysis Analysis of pregnancy outcomes of pregnant women during the epidemic of new coronavirus pneumonia in Hubei province Maternal and perinatal outcomes with COVID-19: a systematic review of 108 pregnancies Maternal and perinatal characteristics and outcomes of pregnancies complicated with COVID-19 in Kuwait Analysis of maternal coronavirus infections and neonates born to mothers with 2019-nCoV; a systematic review COVID-19 infection among asymptomatic and symptomatic pregnantwomen: two weeks of confirmed presentations to an affiliated pair of New York City hospitals Maternal COVID-19 infection, clinical characteristics, pregnancy, and neonatal outcome: a prospective cohort study Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study A systematic scoping review of COVID-19 during pregnancy and childbirth Clinical and CT imaging features of the COVID-19 pneumonia: focus on pregnant women and children Maternal and neonatal outcomes associated with COVID-19 infection: A systematic review PLoS ONE 2019-nCoV epidemic: what about pregnancies? COVID-19 infection during pregnancy -maternal and perinatal outcomes: a tertiary care centre study Maternal and perinatal outcomes in patients with suspected COVID-19 and their relationship with a negative RT-PCR result Zika virus infection at different pregnancy stages: anatomopathological findings, target cells and viral persistence in placental tissues Histopathological analysis of placentas with congenital cytomegalovirus infection Dengue infection in pregnancy and its impact on the placenta Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction Maternal vascular malperfusion of the placental bed Repeated lipopolysaccharide exposure leads to placental endotoxin tolerance Is midtrimester short cervix a sign of intraamniotic inflammation? Viral Infections during pregnancy New insights into the relationship between viral infection and pregnancy complications Pneumonia and pregnancy outcomes: a nationwide population-based study Antimalarial drugs for treating and preventing malaria in pregnant and lactating women A randomized, controlled trial of Ebola virus disease therapeutics Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-a prospective cohort study from the German multiple sclerosis and pregnancy registry A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes Inclusion of pregnant women in COVID-19 treatment trials: a review and global call to action Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Dexamethasone in hospitalized patients with Covid-19 COVID 19 in pregnancy; obstetrical and neonatal outcomes: a retrospective comparative study Maternal inflammation, growth retardation, and preterm birth: insights into adult cardiovascular disease SARS-CoV-2 prevalence and maternal-perinatal outcomes among pregnant women admitted for delivery: Experience from COVID-19-dedicated maternity hospital in Jammu The authors declare that there are no conflict of interests. This study has been approved by the Institutional Ethics Committee of Government medical college (GMC) Jammu. https://orcid.org/0000-0002-2427-6058